Cycle Pharmaceuticals Acquires Applied Therapeutics

Acquisition expands Cycle's rare disease drug portfolio.

Feb. 3, 2026 at 7:55am

Got story updates? Submit your updates here. ›

Cycle Group Holdings Limited, a pharmaceutical company focused on rare diseases, has completed the acquisition of NASDAQ-listed Applied Therapeutics, Inc. Applied's lead drug candidate, govorestat, is a novel treatment for several rare central nervous system metabolic disorders.

Why it matters

The acquisition allows Cycle to expand its portfolio of rare disease treatments, an area the company has been focused on since its founding in 2012. Applied's govorestat drug candidate addresses several unmet needs in the rare disease community.

The details

Cycle will fund the acquisition from its existing cash reserves. Applied Therapeutics is a clinical-stage biopharmaceutical company whose lead drug candidate, govorestat, is being developed to treat rare CNS metabolic disorders like Classic Galactosemia, Charcot-Marie-Tooth Sorbitol Dehydrogenase Deficiency (CMT-SORD), and phosphomannomutase 2 congenital disorder of glycosylation (PMM2-CDG), for which there are currently no FDA-approved treatments.

  • Cycle completed the acquisition on February 3, 2026.

The players

Cycle Group Holdings Limited

A pharmaceutical company founded in 2012 that focuses on delivering drug treatments and product support to the rare disease community.

Applied Therapeutics, Inc.

A NASDAQ-listed, clinical-stage biopharmaceutical company whose lead drug candidate, govorestat, is being developed to treat rare CNS metabolic disorders.

James Harrison

CEO of Cycle Pharmaceuticals.

Got photos? Submit your photos here. ›

What they’re saying

“Cycle was founded with a commitment to support patients living with rare metabolic diseases. From our beginnings with NITYR®, we have grown to offer three therapies for this community. With Applied Therapeutics now a part of the Cycle group, we can look to expand further in this area. Our focus remains the same: to bring meaningful, reliable treatments to the patients and families who need them most.”

— James Harrison, CEO, Cycle Pharmaceuticals

The takeaway

The acquisition of Applied Therapeutics strengthens Cycle Pharmaceuticals' position as a leader in developing treatments for rare metabolic diseases, an underserved area of healthcare that the company has been focused on since its founding.